Search
Cytosorbents Corp
CTSOAdd to Watchlist
5.750USD
-0.010-0.17%
Close 09-18 16:00（ET）
18.54MMarket Cap
LossP/E TTM
More Details of Cytosorbents Corp Company
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Cytosorbents Corp Profile
Ticker SymbolCTSO
Company nameCytosorbents Corp
IPO dateJun 17, 2005
CEOChan (Phillip P)
Number of employees149
Security typeOrdinary Share
Fiscal year-endJun 17
Address305 College Road East
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone19733298885
Websitehttps://cytosorbents.com/
Ticker SymbolCTSO
IPO dateJun 17, 2005
CEOChan (Phillip P)
Company Executives of Cytosorbents Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip P. Chan, M.D., Ph.D.
Dr. Phillip P. Chan, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
82.52K
+16.69%
Mr. Vincent J. Capponi
Mr. Vincent J. Capponi
President, Chief Operating Officer
President, Chief Operating Officer
23.56K
+8.80%
Mr. Peter J. (Pete) Mariani, CPA
Mr. Peter J. (Pete) Mariani, CPA
Chief Financial Officer
Chief Financial Officer
10.83K
+46.16%
Mr. Alan D. Sobel, CPA
Mr. Alan D. Sobel, CPA
Independent Director
Independent Director
6.42K
+38.92%
Ms. Jiny Kim
Ms. Jiny Kim
Independent Director
Independent Director
426.00
--
Dr. Edward R. Jones, M.D.
Dr. Edward R. Jones, M.D.
Independent Director
Independent Director
--
--
Mr. Michael G. Bator
Mr. Michael G. Bator
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Efthymios N. Deliargyris, M.D.
Dr. Efthymios N. Deliargyris, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip P. Chan, M.D., Ph.D.
Dr. Phillip P. Chan, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
82.52K
+16.69%
Mr. Vincent J. Capponi
Mr. Vincent J. Capponi
President, Chief Operating Officer
President, Chief Operating Officer
23.56K
+8.80%
Mr. Peter J. (Pete) Mariani, CPA
Mr. Peter J. (Pete) Mariani, CPA
Chief Financial Officer
Chief Financial Officer
10.83K
+46.16%
Mr. Alan D. Sobel, CPA
Mr. Alan D. Sobel, CPA
Independent Director
Independent Director
6.42K
+38.92%
Ms. Jiny Kim
Ms. Jiny Kim
Independent Director
Independent Director
426.00
--
Dr. Edward R. Jones, M.D.
Dr. Edward R. Jones, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Cytosorbents Corp?
The top five shareholders of Cytosorbents Corp are: Dr. Phillip P. Chan, M.D., Ph.D.
How many institutions hold shares of Cytosorbents Corp (CTSO)?
As of 2026Q1, 97 institutions hold shares of Cytosorbents Corp, with a combined market value of approximately 16.20M, accounting for 25.84% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1030604.00.